Javier A Menendez

Summary

Publications

  1. ncbi request reprint Inhibition of fatty acid synthase-dependent neoplastic lipogenesis as the mechanism of gamma-linolenic acid-induced toxicity to tumor cells: an extension to Nwankwo's hypothesis
    Javier A Menendez
    Department of Medicine, Evanston Northwestern Healthcare Research Institute, 1001 Unviersity Place, Evanston, IL 60201, USA
    Med Hypotheses 64:337-41. 2005
  2. ncbi request reprint HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail"
    Javier A Menendez
    Fundació d Investigació Biomèdica de Girona Dr Josep Trueta IdIBGi, Girona, Catalonia Spain
    Clin Transl Oncol 8:812-20. 2006
  3. ncbi request reprint Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells
    Javier A Menendez
    Department of Medicine, Evanston Northwestern Healthcare Research Institute, 1001 University Place, Evanston, IL 60201, USA
    Med Hypotheses 64:997-1001. 2005
  4. ncbi request reprint Mediterranean dietary traditions for the molecular treatment of human cancer: anti-oncogenic actions of the main olive oil's monounsaturated fatty acid oleic acid (18:1n-9)
    Javier A Menendez
    Fundació d Investigació Biomèdica de Girona Dr Josep Trueta IdIBGi, Girona, Catalonia, Spain
    Curr Pharm Biotechnol 7:495-502. 2006
  5. ncbi request reprint Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids?
    Javier A Menendez
    Department of Medicine, Evanston Northwestern Healthcare Research Institute, 1001 University Place, Evanston, IL 60201, USA
    Med Hypotheses 64:342-9. 2005
  6. ncbi request reprint In support of fatty acid synthase (FAS) as a metabolic oncogene: extracellular acidosis acts in an epigenetic fashion activating FAS gene expression in cancer cells
    Javier A Menendez
    Department of Medicine, Breast Cancer Translational Research Laboratory, Evanston Northwestern Healthcare Research Institute, Evanston, Illinois 60201, USA
    J Cell Biochem 94:1-4. 2005
  7. ncbi request reprint Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer
    Cristina Oliveras-Ferraros
    Catalan Institute of Oncology ICO, Dr Josep Trueta University Hospital of Girona, E 17007 Girona, Catalonia, Spain
    Int J Oncol 33:1165-76. 2008
  8. pmc tabAnti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra-Virgin Olive Oil (EVOO)
    Javier A Menendez
    Catalan Institute of Oncology ICO Health Services Division of Catalonia, Catalonia, Spain
    BMC Cancer 8:377. 2008
  9. ncbi request reprint Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation
    Javier A Menendez
    Department of Medicine, Breast Cancer Translational Research Laboratory, Evanston Northwestern Healthcare Research Institute, Evanston, Illinois 60201, USA
    Mol Carcinog 41:164-78. 2004
  10. ncbi request reprint Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity
    Javier A Menendez
    Department of Medicine, Breast Cancer Translational Research Laboratory, Evanston Northwestern Healthcare Research Institute ENHRI, Evanston, IL 60201, USA
    Int J Cancer 115:19-35. 2005

Collaborators

Detail Information

Publications92

  1. ncbi request reprint Inhibition of fatty acid synthase-dependent neoplastic lipogenesis as the mechanism of gamma-linolenic acid-induced toxicity to tumor cells: an extension to Nwankwo's hypothesis
    Javier A Menendez
    Department of Medicine, Evanston Northwestern Healthcare Research Institute, 1001 Unviersity Place, Evanston, IL 60201, USA
    Med Hypotheses 64:337-41. 2005
    ....
  2. ncbi request reprint HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail"
    Javier A Menendez
    Fundació d Investigació Biomèdica de Girona Dr Josep Trueta IdIBGi, Girona, Catalonia Spain
    Clin Transl Oncol 8:812-20. 2006
    ....
  3. ncbi request reprint Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells
    Javier A Menendez
    Department of Medicine, Evanston Northwestern Healthcare Research Institute, 1001 University Place, Evanston, IL 60201, USA
    Med Hypotheses 64:997-1001. 2005
    ....
  4. ncbi request reprint Mediterranean dietary traditions for the molecular treatment of human cancer: anti-oncogenic actions of the main olive oil's monounsaturated fatty acid oleic acid (18:1n-9)
    Javier A Menendez
    Fundació d Investigació Biomèdica de Girona Dr Josep Trueta IdIBGi, Girona, Catalonia, Spain
    Curr Pharm Biotechnol 7:495-502. 2006
    ..Only then we will know whether the old "Mediterranean dietary traditions" will become a new molecular approach in the management of cancer disease...
  5. ncbi request reprint Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids?
    Javier A Menendez
    Department of Medicine, Evanston Northwestern Healthcare Research Institute, 1001 University Place, Evanston, IL 60201, USA
    Med Hypotheses 64:342-9. 2005
    ....
  6. ncbi request reprint In support of fatty acid synthase (FAS) as a metabolic oncogene: extracellular acidosis acts in an epigenetic fashion activating FAS gene expression in cancer cells
    Javier A Menendez
    Department of Medicine, Breast Cancer Translational Research Laboratory, Evanston Northwestern Healthcare Research Institute, Evanston, Illinois 60201, USA
    J Cell Biochem 94:1-4. 2005
    ..These findings, altogether, support the "metabolic oncogene" theory for FAS overexpression in cancer cells...
  7. ncbi request reprint Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer
    Cristina Oliveras-Ferraros
    Catalan Institute of Oncology ICO, Dr Josep Trueta University Hospital of Girona, E 17007 Girona, Catalonia, Spain
    Int J Oncol 33:1165-76. 2008
    ....
  8. pmc tabAnti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra-Virgin Olive Oil (EVOO)
    Javier A Menendez
    Catalan Institute of Oncology ICO Health Services Division of Catalonia, Catalonia, Spain
    BMC Cancer 8:377. 2008
    ..We here investigated the anti-HER2 effects of phenolic fractions directly extracted from Extra Virgin Olive Oil (EVOO) in cultured human breast cancer cell lines...
  9. ncbi request reprint Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation
    Javier A Menendez
    Department of Medicine, Breast Cancer Translational Research Laboratory, Evanston Northwestern Healthcare Research Institute, Evanston, Illinois 60201, USA
    Mol Carcinog 41:164-78. 2004
    ..Our observations strongly suggest that inhibition of FAS activity may provide a new molecular avenue for chemotherapeutic prevention and/or treatment of Her-2/neu-related breast carcinomas...
  10. ncbi request reprint Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity
    Javier A Menendez
    Department of Medicine, Breast Cancer Translational Research Laboratory, Evanston Northwestern Healthcare Research Institute ENHRI, Evanston, IL 60201, USA
    Int J Cancer 115:19-35. 2005
    ....
  11. pmc Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells
    Javier A Menendez
    Department of Medicine, Evanston Northwestern Healthcare, 1001 University Place, Evanston, IL 60201, USA
    Proc Natl Acad Sci U S A 101:10715-20. 2004
    ....
  12. doi request reprint Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205
    Sílvia Cufí
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Cell Cycle 11:1235-46. 2012
    ....
  13. ncbi request reprint Effect of gamma-linolenic acid on the transcriptional activity of the Her-2/neu (erbB-2) oncogene
    Javier A Menendez
    Department of Medicine, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, USA
    J Natl Cancer Inst 97:1611-5. 2005
    ..Concurrent treatments of Her-2/neu-overexpressing cancer cells with GLA and the anti-Her-2/neu antibody trastuzumab led to synergistic increases in apoptosis and reduced growth and colony formation...
  14. ncbi request reprint Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin)
    Cristina Oliveras-Ferraros
    Catalan Institute of Oncology ICO, E 17007 Girona, Catalonia, Spain
    Int J Oncol 37:669-78. 2010
    ....
  15. doi request reprint Crude phenolic extracts from extra virgin olive oil circumvent de novo breast cancer resistance to HER1/HER2-targeting drugs by inducing GADD45-sensed cellular stress, G2/M arrest and hyperacetylation of Histone H3
    Cristina Oliveras-Ferraros
    Catalan Institute of Oncology, 2Girona Biomedical Research Institute, Girona, Catalonia, Spain
    Int J Oncol 38:1533-47. 2011
    ..Oleaceae secoiridoids could provide a valuable phytochemical platform for the design of more pharmacologically active second-generation phytopharmaceutical anti-breast cancer molecules with a unique mode of action...
  16. pmc Ser2481-autophosphorylated mTOR colocalizes with chromosomal passenger proteins during mammalian cell cytokinesis
    Alejandro Vazquez-Martin
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology ICO, Girona, Catalonia, Spain
    Cell Cycle 11:4211-21. 2012
    ....
  17. doi request reprint Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin)
    Cristina Oliveras-Ferraros
    Catalan Institute of Oncology ICO, Avenida de Francia s n, Girona, Catalonia, Spain
    Biochem Biophys Res Commun 397:27-33. 2010
    ..Intrinsic genetic plasticity to efficiently drive the emergence of the CD44(pos)/CD24(neg/low) mesenchymal phenotype may account for de novo resistance to HER2 targeting therapies in basal-like BC carrying HER2 gene amplification...
  18. doi request reprint Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth
    Alejandro Vazquez-Martin
    Catalan Institute of Oncology ICO, Catalonia, Spain
    J Cell Physiol 226:52-7. 2011
    ..These findings, altogether, may provide crucial insights concerning clinical studies aimed to accurately describe HER2 ECD as a potential predictor of response or resistance to the HER2-targeted drugs trastuzumab and lapatinib...
  19. ncbi request reprint Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells
    Alejandro Vazquez-Martin
    Catalan Institute of Oncology ICO Health Services Division of Catalonia, Catalonia, Spain
    Int J Oncol 31:769-76. 2007
    ....
  20. pmc Metformin: multi-faceted protection against cancer
    Sonia del Barco
    Medical Oncology, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Oncotarget 2:896-917. 2011
    ..Current and future clinical trials will elucidate whether metformin has the potential to be used in preventive and treatment settings as an adjuvant to current cancer therapeutics...
  21. ncbi request reprint Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linoleni
    Javier A Menendez
    Department of Medicine, Evanston Northwestern Research Institute, Evanston, IL 60201, USA
    Int J Oncol 24:1369-83. 2004
    ....
  22. ncbi request reprint Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus
    Alejandro Vazquez-Martin
    Unit of Translational Research, Catalan Institute of Oncology Girona, Girona, Spain
    Cell Cycle 10:1295-302. 2011
    ....
  23. pmc Phenolic secoiridoids in extra virgin olive oil impede fibrogenic and oncogenic epithelial-to-mesenchymal transition: extra virgin olive oil as a source of novel antiaging phytochemicals
    Alejandro Vazquez-Martin
    Catalan Institute of Oncology, Girona, Catalonia, Spain
    Rejuvenation Res 15:3-21. 2012
    ....
  24. doi request reprint Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells
    Cristina Oliveras-Ferraros
    Unit of Translational Research, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Invest New Drugs 30:846-52. 2012
    ....
  25. ncbi request reprint Serine 2481-autophosphorylation of mammalian target of rapamycin (mTOR) couples with chromosome condensation and segregation during mitosis: confocal microscopy characterization and immunohistochemical validation of PP-mTOR(Ser2481) as a novel high-contra
    Eugeni Lopez-Bonet
    Department of Pathology, Dr Josep Trueta University Hospital of Girona, Catalonia, Spain
    Int J Oncol 36:107-15. 2010
    ..These findings warrant forthcoming studies to confirm both the accuracy and the prognostic value of PP-mTOR(Ser2481) as a novel high-contrast immunohistochemical mitosis marker in larger populations of human breast carcinomas...
  26. pmc The mitochondrial H(+)-ATP synthase and the lipogenic switch: new core components of metabolic reprogramming in induced pluripotent stem (iPS) cells
    Alejandro Vazquez-Martin
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Spain
    Cell Cycle 12:207-18. 2013
    ....
  27. doi request reprint Metformin is synthetically lethal with glucose withdrawal in cancer cells
    Javier A Menendez
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Cell Cycle 11:2782-92. 2012
    ....
  28. pmc Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs
    Bruna Corominas-Faja
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Spain
    Aging (Albany NY) 4:480-98. 2012
    ....
  29. pmc Metformin and the ATM DNA damage response (DDR): accelerating the onset of stress-induced senescence to boost protection against cancer
    Javier A Menendez
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Aging (Albany NY) 3:1063-77. 2011
    ....
  30. pmc Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions
    Alejandro Vazquez-Martin
    Unit of Translational Research, Catalan Institute of Oncology Girona, Avenida de Francia s n, E 17007 Girona, Catalonia, Spain
    Drug Resist Updat 14:212-23. 2011
    ....
  31. ncbi request reprint Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients
    Alejandro Vazquez-Martin
    Catalan Institute of Oncology, Health Services Division of Catalonia, Catalonia, Spain
    Int J Oncol 35:1369-76. 2009
    ....
  32. ncbi request reprint Mediterranean diet, olive oil and cancer
    Ramon Colomer
    Medical Oncology, Institut Catala d Oncologia, Hospital de Girona Dr Josep Trueta, Girona, Spain
    Clin Transl Oncol 8:15-21. 2006
    ..Indeed, OA-induced transcriptional repression of HER2 oncogene may represent a novel genomic explanation linking "Mediterranean diet", olive oil and cancer as it seems to equally operate in various types of Her-2/neu-related carcinomas...
  33. ncbi request reprint A genomic explanation connecting "Mediterranean diet", olive oil and cancer: oleic acid, the main monounsaturated fatty acid of olive oil, induces formation of inhibitory "PEA3 transcription factor-PEA3 DNA binding site" complexes at t
    Javier A Menendez
    Department of Medicine, Evanston Northwestern Healthcare Research Institute, 1001 University Place, Evanston, IL 60201, and Department of Medicine, Northwestern University Feinberg, School of Medicine, Chicago, IL, USA
    Eur J Cancer 42:2425-32. 2006
    ..OA-induced transcriptional repression of Her-2/neu through the action of PEA3 protein at the promoter level may represent a novel mechanism linking "Mediterranean diet" and cancer...
  34. ncbi request reprint Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression
    Javier A Menendez
    Department of Medicine, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, USA
    J Clin Oncol 24:3735-46. 2006
    ..The decision for treating breast cancer patients with trastuzumab is based on HER-2 amplification and/or overexpression...
  35. ncbi request reprint AlphaVbeta3 integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancer
    Luciano Vellon
    Department of Medicine, Breast Cancer Translational Research Laboratory, Evanston Northwestern Healthcare Research Institute, 1001 University Place, Evanston, IL 60201, USA
    Oncogene 24:3759-73. 2005
    ..This work supports additional studies concerning the use of integrin antagonists as dual therapeutic agents in breast cancer, targeting both, endothelial and tumor cells...
  36. doi request reprint Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment
    Cristina Oliveras-Ferraros
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Oncol Rep 27:1887-92. 2012
    ....
  37. ncbi request reprint Raptor, a positive regulatory subunit of mTOR complex 1, is a novel phosphoprotein of the rDNA transcription machinery in nucleoli and chromosomal nucleolus organizer regions (NORs)
    Alejandro Vazquez-Martin
    Unit of Translational Research, Catalan Institute of Oncology Girona, Girona Biomedical Research Institute, Girona, Spain
    Cell Cycle 10:3140-52. 2011
    ..Nucleolar- and NOR-associated P-Raptor (Ser706) may physically link mTORC1 signaling to ever-growing nucleolus plurifunctionality including ribosome biogenesis, cell stress sensor and cell cycle/aging control...
  38. ncbi request reprint DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes
    Javier A Menendez
    Department of Medicine, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, USA
    Int J Mol Med 18:1081-7. 2006
    ....
  39. doi request reprint Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies
    Cristina Oliveras-Ferraros
    Unit of Translational Research, Catalan Institute of Oncology Girona, Avenida de Francia s n, E 17007 Girona, Catalonia, Spain
    Biochem Biophys Res Commun 407:412-9. 2011
    ..Our current findings may be extremely helpful to design successful combinatorial strategies aimed to circumvent the occurrence of de novo resistance to HER2-directed drugs using survivin antagonists...
  40. ncbi request reprint An easy, rapid and objective mathematical method to identify fatty acid synthase (oncogenic antigen-519) modulators with potential anticancer value
    Ruth Lupu
    Department of Medicine, Northwestern University Feinberg School of Medicine, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, USA
    Clin Transl Oncol 10:219-26. 2008
    ..This "C75-sensitivity test" might offer an easy, rapid and objective method to identify FASN inhibitors with potential anticancer value in human cancer...
  41. pmc Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin)
    Cristina Oliveras-Ferraros
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Cell Cycle 11:4020-32. 2012
    ..The systematic determination of SLUG/SNAIL2 as a stem/CD44+CD24(-/low) cell-associated protein may improve the therapeutic management of HER2+ breast carcinomas...
  42. doi request reprint Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line mod
    Cristina Oliveras-Ferraros
    Unit of Translational Research, Catalan Institute of Oncology Girona, ICO Girona, E 17007 Girona, Catalonia, Spain
    Int J Oncol 39:1455-79. 2011
    ....
  43. doi request reprint The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells
    Alejandro Vazquez-Martin
    Catalan Institute of Oncology, Girona ICO Girona, Dr Josep Trueta University Hospital, Ctra França s n, 17007, Girona, Catalonia, Spain
    Breast Cancer Res Treat 126:355-64. 2011
    ....
  44. ncbi request reprint AMPK: Evidence for an energy-sensing cytokinetic tumor suppressor
    Alejandro Vazquez-Martin
    Catalan Institute of Oncology Health Services Division of Catalonia, Catalonia, Spain
    Cell Cycle 8:3679-83. 2009
    ....
  45. ncbi request reprint Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cells
    Javier A Menendez
    Department of Medicine, Evanston Northwestern Research Institute, Evanston, IL 60201, USA
    Oncol Rep 12:411-22. 2004
    ..We suggest that pharmacological inhibition of FAS activity is a novel molecular approach to enhance the cytotoxic effects of existing chemotherapeutic agents in human breast cancer...
  46. pmc Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin)
    Begoña Martin-Castillo
    Unit of Clinical Research, Catalan Institute of Oncology Girona ICO Girona, Catalonia, Spain
    Cell Cycle 12:225-45. 2013
    ..g., luminal/HER2 vs. basal/HER2) would distinctly benefit from trastuzumab-based therapy ab initio...
  47. pmc Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: a new family of gerosuppressant agents
    Javier A Menendez
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Spain
    Cell Cycle 12:555-78. 2013
    ....
  48. doi request reprint Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation
    Cristina Oliveras-Ferraros
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Cell Cycle 11:865-70. 2012
    ..Restored antigenicity and immunogenicity of tumor cells may represent a previously unrecognized primary mode of action underlying the cancer-preventive effects of metformin...
  49. doi request reprint Polo-like kinase 1 directs the AMPK-mediated activation of myosin regulatory light chain at the cytokinetic cleavage furrow independently of energy balance
    Alejandro Vazquez-Martin
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Spain
    Cell Cycle 11:2422-6. 2012
    ....
  50. ncbi request reprint Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a
    Cristina Oliveras-Ferraros
    Catalan Institute of Oncology Girona ICO Girona, Girona, Catalonia, Spain
    Cell Cycle 10:1144-51. 2011
    ....
  51. ncbi request reprint Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage
    Javier A Menendez
    Department of Medicine, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, USA
    Int J Oncol 26:649-59. 2005
    ....
  52. ncbi request reprint Does endogenous fatty acid metabolism allow cancer cells to sense hypoxia and mediate hypoxic vasodilatation? Characterization of a novel molecular connection between fatty acid synthase (FAS) and hypoxia-inducible factor-1alpha (HIF-1alpha)-related expre
    Javier A Menendez
    Department of Medicine, Evanston Northwestern Healthcare Research Institute, 1001 University Place, Evanston, IL 60201, USA
    J Cell Biochem 94:857-63. 2005
    ....
  53. ncbi request reprint A novel CYR61-triggered 'CYR61-alphavbeta3 integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway
    Javier A Menendez
    Department of Medicine, Breast Cancer Translational Research Laboratory, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, USA
    Oncogene 24:761-79. 2005
    ..The identification of a 'CYR61-alphavbeta3 autocrine loop' in the epithelial compartment of breast carcinoma strongly suggests that targeting alphavbeta3 may simultaneously prevent breast cancer angiogenesis, growth, and chemoresistance...
  54. ncbi request reprint Up-regulation of alphavbeta3 integrin expression is a novel molecular response to chemotherapy-induced cell damage in a heregulin-dependent manner
    Luciano Vellon
    Department of Medicine, Breast Cancer Translational Research Laboratory, Evanston Northwestern Healthcare Research Institute, 1001 University Place, Evanston, IL, USA
    Differentiation 75:819-30. 2007
    ....
  55. ncbi request reprint Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
    Javier A Menendez
    Translational Research Unit, Catalan Institute of Oncology ICO, Health Services Division of Catalonia, Girona Biomedical Research Institute IdIBGi, Medical Oncology, Josep Trueta University Hospital of Girona, 17, 007 Girona, Catalonia, Spain
    Nat Rev Cancer 7:763-77. 2007
    ..FASN, a nearly-universal druggable target in many human carcinomas and their precursor lesions, offers new therapeutic opportunities for metabolically treating and preventing cancer...
  56. ncbi request reprint Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells
    Alejando Vazquez-Martin
    Catalan Institute of Oncology Health Services Division of Catalonia, 17007 Girona, Catalonia, Spain
    Oncol Rep 18:973-80. 2007
    ....
  57. ncbi request reprint A bidirectional "alpha(v)beta(3) integrin-ERK1/ERK2 MAPK" connection regulates the proliferation of breast cancer cells
    Luciano Vellon
    Department of Medicine, Breast Cancer Translational Research Laboratory, Evanston Northwestern Healthcare Research Institute, Evanston, Illinois 60201, USA
    Mol Carcinog 45:795-804. 2006
    ..Collectively, these results strongly suggest the existence of a bidirectional molecular connection alpha(v)beta(3)-ERK1/ERK2 MAPK that would regulate breast cancer cells survival and proliferation...
  58. doi request reprint Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells
    Sílvia Cufí
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain Girona Biomedical Research Institute IdIBGi, Girona, Catalonia, Spain
    Food Chem Toxicol 60:360-8. 2013
    ....
  59. pmc One-carbon metabolism: an aging-cancer crossroad for the gerosuppressant metformin
    Javier A Menendez
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology Girona ICO Girona, Girona, Spain
    Aging (Albany NY) 4:894-8. 2012
    ....
  60. pmc Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency
    Alejandro Vazquez-Martin
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Spain
    Sci Rep 2:964. 2012
    ....
  61. doi request reprint Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells
    Alejandro Vazquez-Martin
    Translational Research Laboratory, Catalan Institute of Oncology ICO, Girona, Spain
    Cell Cycle 11:974-89. 2012
    ..AMPK-activating anti-reprogramming strategies may provide a roadmap for the generation of novel cancer therapies that metabolically target tumor-propagating cells...
  62. ncbi request reprint Oncogenic properties of the endogenous fatty acid metabolism: molecular pathology of fatty acid synthase in cancer cells
    Javier A Menendez
    Foundation of the Recerca Bio Medical Institute of Girona Dr Josep Trueta, University Hospital of Girona, Dr Josep Trueta, Girona, Catalonia, Spain
    Curr Opin Clin Nutr Metab Care 9:346-57. 2006
    ..This review documents our rapidly changing perspectives on the function of fatty acid synthase-catalyzed endogenous fatty acid biogenesis in cancer biology...
  63. ncbi request reprint An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review)
    Laura Ferrer-Soler
    Girona Biomedical Research Institute IdIBGi, Dr Josep Trueta University Hospital of Girona, Girona, Catalonia, Spain
    Int J Mol Med 20:3-10. 2007
    ....
  64. ncbi request reprint Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of scheduling
    Cristina Oliveras-Ferraros
    Metabolism and Cancer Laboratory, Girona Biomedical Research Institute IdIBGi, Dr Josep Trueta University Hospital of Girona, Catalonia, Spain
    Int J Oncol 32:113-20. 2008
    ..The synergism that we have observed may explain the favorable clinical responses that have been achieved in clinical studies, in which patients are administered PTX first, and then GEM...
  65. ncbi request reprint Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75
    Teresa Puig
    Fundació d Investigació Biomèdica de Girona Dr Josep Trueta IdIBGi, Hospital Universitari de Girona Dr Josep Trueta, Girona, Spain
    Breast Cancer Res Treat 109:471-9. 2008
    ..Our results establish EGCG as a potent and specific inhibitor of fatty acid synthesis (FASN), which may hold promise as a target-directed anti-cancer drug...
  66. ncbi request reprint Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators?
    Ruth Lupu
    Department of Medicine, Evanston Northwestern Healthcare Research Institute, 1001 University Place, Evanston, Illinois 60201, USA
    Endocrinology 147:4056-66. 2006
    ....
  67. doi request reprint AMPK-sensed cellular energy state regulates the release of extracellular Fatty Acid Synthase
    Cristina Oliveras-Ferraros
    Catalan Institute of Oncology, Girona ICO Girona, Hospital de Girona Dr Josep Trueta, Ctra França s n, E 17007 Girona, Catalonia, Spain
    Biochem Biophys Res Commun 378:488-93. 2009
    ..FASN release might represent a previously unrecognized mechanism through which AMPK monitor and restores cellular energy state in response to increasing AMP/ATP ratios...
  68. pmc Extracellular fatty acid synthase: a possible surrogate biomarker of insulin resistance
    Jose Manuel Fernandez-Real
    Department of Diabetes, Endocrinology and Nutrition, Institutd Investigació Biomédica de Girona, CIBERobn Fisiopatología de la Obesidad y Nutrición CB06 03 010, Girona, Catalonia, Spain
    Diabetes 59:1506-11. 2010
    ..The aim of this study was to determine whether circulating FASN could be a biomarker of overnutrition-induced metabolic stress and insulin resistance in common metabolic disorders...
  69. ncbi request reprint Orlistat: from antiobesity drug to anticancer agent in Her-2/neu (erbB-2)-overexpressing gastrointestinal tumors?
    Javier A Menendez
    Department of Medicine, Breast Cancer Translational Research Program, Evanston Northwestern Healthcare Research Institute, 1001 University Place, Evanston, Illinois 60201, USA
    Exp Biol Med (Maywood) 230:151-4. 2005
  70. ncbi request reprint The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells
    Alejandro Vazquez-Martin
    Catalan Institute of Oncology, Dr Josep Trueta University Hospital of Girona, Girona, Catalonia, Spain
    Oncol Rep 25:135-40. 2011
    ....
  71. ncbi request reprint Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neu-overexpressing breast cancer
    Javier A Menendez
    Department of Medicine, Evanston Northwestern Healthcare Research Institute, Evanston, Illinois 60201, USA
    Drug News Perspect 18:375-85. 2005
    ..Third, pharmacological inhibition of FAS activity negatively regulates the expression and tyrosine-kinase activity of Her-2/neu-coded p185(Her-2/neu) oncoprotein...
  72. doi request reprint The serine 2481-autophosphorylated form of mammalian Target Of Rapamycin (mTOR) is localized to midzone and midbody in dividing cancer cells
    Alejandro Vazquez-Martin
    Catalan Institute of Oncology ICO Girona, Dr Josep Trueta University Hospital of Girona, Avenida de Francia s n, E 17007 Girona, Catalonia, Spain
    Biochem Biophys Res Commun 380:638-43. 2009
    ..These results reveal for the first time that PP-mTOR(Ser2481) may be unexpectedly involved in the terminal stages of cytokinesis...
  73. ncbi request reprint The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival
    Javier A Menendez
    Department of Medicine, Breast Cancer Translational Research Laboratory, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, USA
    Int J Oncol 26:1507-15. 2005
    ....
  74. ncbi request reprint Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status
    Alejandro Vazquez-Martin
    Catalan Institute of Oncology ICO, Girona, Catalonia, Spain
    Cell Cycle 9:3807-14. 2010
    ....
  75. ncbi request reprint Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer
    Alejandro Vazquez-Martin
    Fundació d Investigació Biomèdica de Girona Dr Josep Trueta IdIBGi, Avenida de Francia s n, 17007 Girona, Catalonia, Spain
    Eur J Cancer 43:1117-24. 2007
    ....
  76. ncbi request reprint Fatty acid synthase-catalyzed de novo fatty acid biosynthesis: from anabolic-energy-storage pathway in normal tissues to jack-of-all-trades in cancer cells
    Javier A Menendez
    Department of Medicine, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, USA
    Arch Immunol Ther Exp (Warsz) 52:414-26. 2004
    ....
  77. doi request reprint Her-2/neu-induced "cytokine signature" in breast cancer
    Alejandro Vazquez-Martin
    Fundación Privada de Investigación Biomédica de Girona Dr Joseph Trueta Instituto Catalá de Oncología de Girona, Catalonia, Spain
    Adv Exp Med Biol 617:311-9. 2008
    ....
  78. ncbi request reprint The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells
    Alejandro Vazquez-Martin
    Catalan Institute of Oncology ICO Health Services Division of Catalonia, Dr Josep Trueta University Hospital of Girona, Avenida de Francia s n, Girona, Catalonia, Spain
    Cell Cycle 8:88-96. 2009
    ..The importance of mTOR/p70S6K1-sensed ROS status at mediating the anti-oncogenic effects of metformin might represent a previously unrecognized linkage molecularly connecting its anti-aging and anti-cancer actions...
  79. ncbi request reprint Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER -2/ neu -overexpressing human breast cancer cells to docetaxel (taxotere)
    Javier A Menendez
    Department of Medicine, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, USA
    Breast Cancer Res Treat 84:183-95. 2004
    ..To the best of our knowledge this is the first study demonstrating that FAS is playing an active role in HER -2/ neu -induced breast cancer chemotherapy resistance...
  80. ncbi request reprint Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?
    Ruth Lupu
    Department of Medicine, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, USA
    Curr Pharm Biotechnol 7:483-93. 2006
    ..5 A resolution X-ray crystallographic map of mammalian FASN, will direct the foundation of a new family of chemotherapeutic agents in cancer history...
  81. doi request reprint Fatty acid synthase: association with insulin resistance, type 2 diabetes, and cancer
    Javier A Menendez
    Catalan Institute of Oncology, Girona Biomedical Research Institute, Hospital Universitari de Girona Josep Trueta, Girona, Catalonia, Spain
    Clin Chem 55:425-38. 2009
    ..An emerging paradigm supports the notion that deregulation of fatty acid synthase (FASN)-catalyzed de novo FA biogenesis could play a central role in the pathogenesis of metabolic diseases sharing the hallmark of insulin-resistance...
  82. ncbi request reprint Analyzing effects of extra-virgin olive oil polyphenols on breast cancer-associated fatty acid synthase protein expression using reverse-phase protein microarrays
    Javier A Menendez
    Girona Biomedical Research Institute, Medical Oncology, Dr Josep Trueta University Hospital of Girona, E 17007 Girona, Catalonia, Spain
    Int J Mol Med 22:433-9. 2008
    ....
  83. pmc Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab
    Alejandro Vazquez-Martin
    Catalan Institute of Oncology ICO, Girona, Catalonia, Spain
    PLoS ONE 4:e6251. 2009
    ..Therapeutic targeting autophagosome formation/function might represent a novel molecular avenue to reduce the emergence of Tzb resistance in HER2-dependent breast carcinomas...
  84. ncbi request reprint Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB
    Javier A Menendez
    Department of Medicine, Evanston Northwestern Research Institute, Evanston, IL 60201, USA
    Int J Oncol 24:591-608. 2004
    ....
  85. ncbi request reprint RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells
    Javier A Menendez
    Department of Medicine, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, USA
    Int J Mol Med 15:33-40. 2005
    ....
  86. doi request reprint Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: molecular mechanisms and therapeutic perspectives
    Javier A Menendez
    Catalan Institute of Oncology ICO Health Services Division of Catalonia, Dr Josep Trueta University Hospital of Girona, Girona, Catalonia, Spain
    Biochim Biophys Acta 1801:381-91. 2010
    ....
  87. doi request reprint The tyrosine kinase receptor HER2 (erbB-2): from oncogenesis to adipogenesis
    Alejandro Vazquez-Martin
    Catalan Institute of Oncology ICO, Girona Biomedical Research Institute IdIBGi, Hospital Universitari de Girona Dr Josep Trueta, Girona, Catalonia, Spain
    J Cell Biochem 105:1147-52. 2008
    ..Our findings not only confirm a non-oncogenic role for HER2 in the process of adipose differentiation but further suggest that HER2 might represent a previously unrecognized target to manage obesity via the lipogenic enzyme FASN...
  88. ncbi request reprint Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells
    Javier A Menendez
    Department of Medicine, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, USA
    Oncogene 23:4945-58. 2004
    ....
  89. pmc Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?
    Javier A Menendez
    Catalan Institute of Oncology ICO, Health Services Division of Catalonia, Girona Biomedical Research Institute IdIBGi, Medical Oncology, Dr, Josep Trueta, University Hospital of Girona, Catalonia, Spain
    Breast Cancer Res 9:111. 2007
    ....
  90. ncbi request reprint The active form of the metabolic sensor: AMP-activated protein kinase (AMPK) directly binds the mitotic apparatus and travels from centrosomes to the spindle midzone during mitosis and cytokinesis
    Alejandro Vazquez-Martin
    Catalan Institute of Oncology ICO and Girona Biomedical Research Institute IdIBGi, Dr Josep Trueta University Hospital, E 17007 Girona, Catalonia, Spain
    Cell Cycle 8:2385-98. 2009
    ....
  91. ncbi request reprint BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer
    Joan Brunet
    Catalan Institute of Oncology ICO Health Services Division of Catalonia, Catalonia, Spain
    Mol Carcinog 47:157-63. 2008
    ..Alternatively, new forthcoming ACCA inhibitors may be relevant in the management of BRCA1-dependent breast cancer susceptibility and development...
  92. ncbi request reprint Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling
    Eugeni Lopez-Bonet
    Department of Pathology, Dr Josep Trueta University Hospital of Girona, E 17007 Girona, Catalonia, Spain
    Oncol Rep 20:1369-74. 2008
    ..Forthcoming studies should definitely determine if the clinico-pathological features of NEBC indeed represent an independent good-prognosis subgroup of BC gene signature...